

# MOLOGEN AG

---

## **MOLOGEN closes second quarter of 2006: Important contracts closed and good prospects although revenues still low**

**Berlin, August 10, 2006.** In the first six months of 2006, MOLOGEN AG (ISIN DE0006637200) secured important contractual agreements and further developed its technology. Thanks to the continued good liquidity position, business prospects are considered to be excellent. The current license negotiations indicate a balanced result for the first eight months of 2006.

In the first half of 2006, MOLOGEN generated EBIT of -1.7 million EUR in the Consolidated Financial Statements prepared in line with IFRS. In the same period of the previous year, EBIT was -1.9 million EUR. The revenues are 0.5 million EUR, slightly above those of the same period of the previous year (0.4 million EUR). The earnings per share amount to -0.20 EUR as compared to -0.31 EUR in the first six months of 2005.

### **Cell-based gene therapy for fighting cancer**

In March, an agreement was concluded with the NMC Group, United Arab Emirates, for the delivery of MOLOGEN-developed cell-based gene therapy. MOLOGEN is to deliver its cancer therapy to hospitals of the NMC Group. However, the approval of the state

authorities is required before patients can be treated. The work begun in April to obtain the necessary treatment authorization is going according to plan. Since the import of the gene therapy has already been approved, the decision of the health authorities is expected in the third quarter.

Preliminary work for a license for the therapy in Europe also got underway. The so-called Innovation Task Force, a committee of EMEA, the European licensing authority, has awarded drug status to the cell-based gene therapy to combat renal cancer. This decision is an important step forward for the further clinical development of this cancer therapy in Europe, as cells other than MOLOGEN's DNA molecules MIDGE and dSLIM have not been classified as drugs from the start.

### **MIDGE vaccine against leishmaniasis**

In April, MOLOGEN concluded a far-reaching license and development agreement for its MIDGE-based vaccine for domestic animals against the infectious disease of leishmaniasis. The contracting party, which wishes to remain anonymous, is one of the world's ten largest veterinary pharmaceutical companies and belongs to a major global

pharmaceutical organization based in the USA.

As well as the upfront and milestone payments, MOLOGEN will obtain sizable proportions of the subsequent revenues. MOLOGEN has received the first payment on time in the form of a signing fee of USD 100,000. After licensing, the marketing of the vaccine will initially focus on Europe, where leishmaniasis is one of the most widespread diseases suffered by pets.

The project is proceeding according to plan. The partner's project team visited MOLOGEN in July and was fully briefed about the production process and quality standards of the leishmaniasis vaccine. Following this, MOLOGEN was commissioned to produce the vaccine for the next development stage.

### **Latest developments**

#### **dSLIM**

To prepare for a hearing at EMEA, the European drug licensing authority, we pushed ahead with the planning for the next clinical study for the application of dSLIM against colorectal cancer. A so-called 'briefing book' was created, which contains the detailed planning of the studies yet to be completed as well as all development data so far. In this hearing, which is scheduled for the fall, the planning of the studies will be agreed with EMEA with regard to the subsequent licensing procedure.

#### **Cell-based gene therapy**

Negotiations continued for the licensing out of the cell-based gene therapy in further regions. As well as India, potential partners were approached in China and Russia, and the business model for marketing the therapy was comprehensively presented.

#### **Website**

To coincide with today's half-yearly report, the company has relaunched its homepage. The newly designed site can as usual be accessed at [www.mologen.com](http://www.mologen.com).

**About MOLOGEN**

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

\*\*\*

**MOLOGEN AG**

Fabeckstr. 30, 14195 Berlin, Germany

**Contact:** Dirk Simon

**E-mail:** investor@mologen.com

**Tel.:** +49-30-84 17 88-13

**Fax:** +49-30-84 17 88-50

**Disclaimer concerning prognoses**

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

**MOLOGEN AG – Consolidated Balance Sheet**  
**according to IFRS as of June 30, 2006**  
**unaudited**

	Note	June 30, 2006 in thou €	Dec 31, 2005 in thou €
<b>ASSETS</b>			
<b>Non-current assets</b>		<b>1,566</b>	<b>1,739</b>
Tangible assets	1	836	915
Intangible assets	2	723	816
Financial assets	3	0	0
Financial assets at equity	4	0	0
Other non-current assets	5	7	8
<b>Current assets</b>		<b>6,650</b>	<b>8,261</b>
Liquid funds	6	6,123	7,831
Trade accounts receivable	7	232	141
Inventory	8	71	87
Other current assets	9	224	202
<b>Total</b>		<b>8,216</b>	<b>10,000</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>			
<b>Non-current liabilities</b>		<b>354</b>	<b>319</b>
Non-current, interest-bearing liabilities	10	46	0
Other non-current liabilities and deferred income	10	227	238
Provisions	11	81	81
<b>Current liabilities</b>		<b>404</b>	<b>603</b>
Trade accounts payable		293	355
Other current liabilities		88	225
Provisions	20	23	23
<b>Shareholders' equity</b>		<b>7,458</b>	<b>9,078</b>
Share capital	13	8,358	8,358
Capital reserve	14	16,659	16,644
Balance sheet loss	15	-17,616	-15,945
Minority interests	16	57	21
<b>Total</b>		<b>8,216</b>	<b>10,000</b>

**MOLOGEN AG – Consolidated Statement of Profit and Loss**  
**according to IFRS for the first half of 2006**  
**unaudited**

	Note	Apr. 1 – June 30		Jan. 1 – June 30	
		2006	2005	2006	2005
		in thou €	in thou €	in thou €	in thou €
<b>Revenues</b>	17	<b>333</b>	<b>289</b>	<b>537</b>	<b>442</b>
<b>Other operating income</b>	18	<b>72</b>	<b>100</b>	<b>77</b>	<b>178</b>
<b>Increase/decrease of stock of finished or unfinished products</b>		<b>-3</b>	<b>4</b>	<b>3</b>	<b>-24</b>
<b>Purchases/expenses for raw materials and supplies</b>	19	<b>-230</b>	<b>-161</b>	<b>-383</b>	<b>-312</b>
<b>Personnel expenses</b>	20	<b>-478</b>	<b>-456</b>	<b>-847</b>	<b>-817</b>
<b>Depreciation</b>	21	<b>-106</b>	<b>-82</b>	<b>-217</b>	<b>-142</b>
<b>Other operating expenses</b>	22	<b>-484</b>	<b>-944</b>	<b>-910</b>	<b>-1,276</b>
<b>Operating result</b>		<b>-896</b>	<b>-1,250</b>	<b>-1,740</b>	<b>-1,951</b>
Financial result	23	31	3	69	8
<b>Result before taxes (and minority interests)</b>		<b>-865</b>	<b>-1,247</b>	<b>-1,671</b>	<b>-1,943</b>
Taxes		0	0	0	0
<b>Result before minority interests</b>		<b>-865</b>	<b>-1,247</b>	<b>-1,671</b>	<b>-1,943</b>
Minority interests	24	-4	-3	0	-1
<b>Annual deficit</b>		<b>-869</b>	<b>-1,250</b>	<b>-1,671</b>	<b>-1,944</b>
Deficit carried forward		0	0	-15,945	-11,551
<b>Balance sheet deficit</b>		<b>-869</b>	<b>-1,250</b>	<b>-17,616</b>	<b>-13,495</b>
<b>Earnings per share (in euros)</b>	25	<b>-0.10</b>	<b>-0.19</b>	<b>-0.20</b>	<b>-0.31</b>

**MOLOGEN AG – Consolidated Statement of Cash Flow**  
**according to IFRS for the first half of 2006**  
**unaudited**

	Note	June 30 2006 in thou €	June 30 2005 in thou €
<b>Cash flow from operating activities</b>			
Annual deficit before tax (and minority interests)		-1,671	-1,943
Depreciation from fixed assets		202	119
Deficit from divestiture of fixed assets		0	3
Decrease in provisions		0	-32
Other non-cash income		92	33
Taxes		0	0
Minority interests		0	-1
Change in trade accounts receivable, inventories and other assets		-96	31
Change in trade accounts payable and other liabilities		-206	121
<b>Net cash used for operating activities</b>		<b>-1,679</b>	<b>-1,669</b>
<b>Cash flow from investing activities</b>			
Purchases of property, plant, and equipment		-23	-74
Purchases of intangible assets		-7	-200
Purchases of financial assets		0	-370
<b>Net cash used for investing activities</b>		<b>-30</b>	<b>-644</b>
<b>Cash flow from financing activities</b>			
Cash receipts from issuing of capital		-51	2,168
Proceeds from the raising of financial loans		52	
<b>Net cash used for financing activities</b>		<b>1</b>	<b>2,168</b>
<b>Total change in liquidity (cash flow)</b>		<b>-1,708</b>	<b>-145</b>
<b>Liquid funds at beginning of period (including securities)</b>		<b>7,831</b>	<b>2,260</b>
<b>Liquid funds at end of period (including securities)</b>	27	<b>6,123</b>	<b>2,115</b>

**MOLOGEN AG – Consolidated Statement of Changes in Shareholders' Equity**  
**according to IFRS for the first half of 2006**  
**in thousand €, excluding share information**  
**unaudited**

	Parent company					Minority shareholders	Group equity	
	Share capital		Deposits paid	Capital reserves	Bal. sh. loss	Equity	Minority equity	
	No. of shares	Capital stock						
<b>Balance as at January 1, 2005</b>	<b>6,172,331</b>	<b>6,172</b>	<b>0</b>	<b>9,212</b>	<b>-11,457</b>	<b>3,927</b>	<b>19</b>	<b>3,946</b>
Capital increase for cash contribution	600,000	600		1,568		2,168		2,168
Value of services rendered by employees (first-time application of IFRS 2, retroactive for previous years)				95	-95	0		0
Value of services rendered by employees (according to IFRS 2) in 2005				43		43		43
Results before minority interests					-1,942	-1,942		-1,942
Minority interests					-1	-1	1	0
<b>Balance as at June 30, 2005</b>	<b>6,772,331</b>	<b>6,772</b>	<b>0</b>	<b>10,918</b>	<b>-13,495</b>	<b>4,195</b>	<b>20</b>	<b>4,215</b>
<b>Balance as at January 1, 2006</b>	<b>8,357,848</b>	<b>8,358</b>	<b>0</b>	<b>16,644</b>	<b>-15,945</b>	<b>9,057</b>	<b>21</b>	<b>9,078</b>
Capital increase for cash contribution				-51		-51		-51
Value of services rendered by employees (according to IFRS 2)				66		66		66
Results before minority interests					-1,671	-1,671		-1,671
Minority interests							36	36
<b>Balance as at June 30, 2006</b>	<b>8,357,848</b>	<b>8,358</b>	<b>0</b>	<b>16,659</b>	<b>-17,616</b>	<b>7,401</b>	<b>57</b>	<b>7,458</b>

**Molgen AG, Berlin**  
**Notes to the Consolidated Financial Statements**  
**for the First half of 2006**

**A Principles and methods**

**1. General principles**

The abridged and unaudited half-yearly financial statements for Mologen AG were prepared in accordance with the same principles, regulations and methods as the audited Consolidated Financial Statements for 2005. The Consolidated Financial Statements for Mologen AG and its subsidiary were prepared in accordance with the International Financial Reporting Standards (IFRS) of the International Accounting Standard Board (IASB), taking into consideration IAS 34, "Interim Reporting".

The reporting period used in these consolidated financial statements is the period from January 01, 2006 until June 30, 2006. The reporting currency is the euro (€). The breakdown of the Balance Sheet is in accordance with the minimum breakdown provided for in IFRS in line with IAS 1. The Statement of Profit and Loss has been prepared in accordance with the cost of production method.

**2. Scope of consolidation**

The scope of consolidation of the MOLOGEN Group includes MOLOGEN as the parent company and Vivotecnia Research S.L. Madrid/Spain (Vivotecnia). The holding of MOLOGEN in Vivotecnia was 89.2% as at June 30, 2006 (June 30, 2005: 97%).

### **3. Consolidation, accounting and valuation principles**

These half-yearly financial statements should be read in conjunction with the audited Consolidated Financial Statements for Mologen AG as at December 31, 2005. The consolidation, accounting and valuation principles contained therein remain unchanged for these financial statements and are therefore not explained in detail (IAS 34.28). No principles other than those mentioned in IAS or IFRS were used in the reporting period.

### **B. Notes on the IFRS Consolidated Balance Sheet**

#### **Assets**

#### **Long-term assets**

##### (1) Property, plant and equipment

In the reporting period, the net value of the property, plant and equipment decreased by T€ 79 from T€ 915 (December 31, 2005) to T€ 836. Against standard depreciation there were investments of T€ 23.

##### (2) Intangible assets

In the reporting period, the value of the intangible assets in the Balance Sheet decreased by T€ 93 to T€ 723 (December 31, 2005: T€ 816). The intangible assets are comprised of patents/licenses acquired (residual book value: T€ 685) and software (residual book value: T€ 38).

(3) Financial assets

The financial assets of MOLOGEN are comprised of loans to companies with which an investment relationship exists, as well as other loans. They are valued at the lower fair value and amount to € 2 as at June 30, 2006 (June 30, 2005: € 2).

(4) Financial assets at equity

MOLOGEN has a 28.3% investment relationship with bcd biomedical consulting + development GmbH, Berlin (in short: bcd GmbH). In February 2004, bcd applied for insolvency. The book value of the investment in bcd GmbH and the loan receivable from bcd GmbH are each estimated as having a pro memoria figure of € 1 (December 31, 2005: € 1).

(5) Other assets

The other long-term assets are comprised of staff loans, and amount to T€ 7 (December 31, 2005: T€ 8) and have a remaining life as at the balance sheet date of over a year.

**Short-term assets**

(6) Liquid funds

As at June 30, 2006, the liquid funds amounted to T€ 6,123 (December 31, 2005: T€ 7,831) and are comprised of overnight money and time deposits with banks with a remaining life of less than a year.

Fixed-term deposits in the amount of T€ 74 (December 31, 2000: T€ 74) are pledged. Of these, T€ 49 (December 31, 2005: T€ 49) are used as collateral for rental guaranties and T€ 25 (December 31, 2005: T€ 25) as collateral for a bank guarantee for a long-term loan of T€ 77 (December 31, 2005: T€ 77) from the Spanish Ministry for Science (loan posted under "Long-term Liabilities", (10)).

(7) Trade accounts receivable

The trade accounts receivable in the amount of T€ 232 (December 31, 2005: T€ 141) are posted in the balance sheet at nominal value and as at the balance sheet date all have a remaining life of less than a year.

(8) Inventories

The stock of inventories is estimated at their cost of acquisition or production.

As at June 30, 2006, the inventories amount to T€ 71 (December 31, 2005: T€ 87) and are comprised as follows:

	<u>June 30, 2006</u>	<u>Dec 31, 2005</u>
	T€	T€
Finished goods and merchandise	71	87
Unfinished goods and services	0	0
	<u><b>71</b></u>	<u><b>87</b></u>

In the fiscal year, value adjustments to inventories in the amount of T€ 15 (December 31, 2005: T€ 48) were formed, which were recorded as expenditure in accordance with IAS 2.34.

There are no reinstatements of original values or pledges as collateral.

(9) Other assets

The amount of T€ 224 (December 31, 2005: T€ 202) entered in the Balance Sheet is comprised as follows:

	<u>June 30, 2006</u>	<u>Dec 31, 2005</u>
	T€	T€
Tax refund claims	151	146
Due from capital investment bonus to the local tax office	3	2
Other receivables	70	54
	<b><u>224</u></b>	<b><u>202</u></b>

The amounts listed under tax refund claims are comprised of receivables and liabilities to the same authorities and may be netted out in accordance with IAS 12.71.

**Liabilities****Long-term debts**(10) Long-term interest-bearing debts, other debts and items of accrual and deferral

	<u>June 30, 2006</u>	<u>Dec 31, 2005</u>
	T€	T€
Debts from loans, rent deposits and leasing	96	97
Items of accrual and deferral	76	86
Long-term interest-bearing debts	46	0
Other	55	55
	<b><u>273</u></b>	<b><u>238</u></b>

Long-terms debts from loans, rent deposits and leasing in the amount of T€ 96 (December 31, 2005: T€ 97) involve a loan from the Spanish Ministry of Science to Vivotecnia in the amount of T€ 77 (December 31, 2005: T€ 11) and rent deposits in the amount of T€ 11 (December 31, 2005: T€ 11) for the subletting of rooms as well as future leasing payments in the amount of T€ 8 (December 31, 2005: T€ 9).

The amounts shown under items of accrual and deferral involve public contributions for assets. The special items formed are written back over the useful life of the individual assets.

#### (11) Provisions

The long-term provisions include property acquisition tax (T€ 81, December 31, 2005: T€ 81).

### **Current liabilities**

#### (12) Trade accounts payable, other liabilities and provisions

The following lists the current liabilities and provisions with a remaining life of up to 1 year.

	<u>June 30, 2006</u>	<u>Dec 31, 2005</u>
	T€	T€
Current liabilities	293	355
Liabilities from social security and income and church tax	40	114
Provisions	23	23
Other liabilities	48	111
	<b><u>404</u></b>	<b><u>603</u></b>

**Provisions schedule**

	Brought forward to Jan 01, 06	Used as at June 30, 06	Written back as at June 30, 06	Transferred as at June 30, 06	Balance as at June 30, 06
	T€	T€	T€	T€	T€
Reserves for inven- tor's compensation	20	0	0	0	20
Reserves for corpo- ration income tax (Vivotecnia)	3	0	0	0	3
	<b>23</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>23</b>

**Shareholders' equity**(13) Share capital

The capital stock of MOLOGEN, consisting of € 8,357,848,00 divided into 8,357,848 individual no-par ordinary shares issued to the bearer (bearer shares) with an accounting value in the capital stock of € 1.00 per bearer share, is reported as share capital. In the reporting period, MOLOGEN did not implement any measures affecting the capital stock.

(14) Capital reserves

The development of the other items under shareholders' equity is shown in Annex 3. The capital reserves were formed voluntarily. In them are posted elements of shareholders' equity which accrue from outside via the share capital as well as the setting off of goodwill resulting from first-time consolidation. As required by IAS 32.37, the costs of T€ 51 incurred for the procurement of shareholders' equity are taken into account in the capital reserves. These refer to costs incurred in the reporting period for the capital increases implemented in the fiscal year 2005 and which had not been taken into consideration in the previous year's liabilities.

(15) Balance sheet loss

The balance sheet loss contains a loss carryforward of T€ 15,945.

(16) Minority interests

This item records the proportion of shareholders' equity in Vivotecnia, T€ 57 (December 31, 2005: T€ 21) allocated to minority partners. The proportion of the minority interests in the profit for the year is included in the Statement of Profit and Loss under the item "Minority Interests."

**C. Notes to the Consolidated Statement of Profit and Loss**(17) Revenues

As at June 30, 2006, revenues amounted to T€ 537 (June 30, 2005: T€ 442).

	June 30, 06	June 30, 06	June 30, 05	June 30, 05
	<u>H 1 / 06</u>	<u>Q2 / 06</u>	<u>H 1 / 05</u>	<u>Q2 / 05</u>
	T€	T€	T€	T€
Goods and services	459	255	442	289
Licensing and distribution rights	78	78	0	0
	<b>537</b>	<b>333</b>	<b>442</b>	<b>289</b>

(18) Other operating income

As at June 30, 2006, "Other operating income" amounted to T€ 77 (June 30, 2005: T€ 178).

	June 30, 06	June 30, 06	June 30, 05	June 30, 05
	<u>H 1 / 06</u>	<u>Q2 / 06</u>	<u>H 1 / 05</u>	<u>Q2 / 05</u>
	T€	T€	T€	T€
Income from grants	64	64	151	80
Other	13	8	27	20
	<b>77</b>	<b>72</b>	<b>178</b>	<b>100</b>

The amount posted under other operating income as grants refers to project grants from the Investitionsbank Berlin as well as from the Federal Ministry for Education and Research.

The grants for research expenditure are connected with a range of commitments. These can be fulfilled according to the latest information. In the event this does not occur, repayment obligations in the amount of T€ 559 (June 30, 2005: T€ 338) may arise.

(19) Purchases

	June 30, 06	June 30, 06	June 30, 05	June 30, 05
	<u>H 1 / 06</u>	<u>Q2 / 06</u>	<u>H 1 / 05</u>	<u>Q2 / 05</u>
	T€	T€	T€	T€
Expenses for raw materials and supplies	287	175	233	125
Expenses for services used	96	55	79	36
	<b>383</b>	<b>230</b>	<b>312</b>	<b>161</b>

(20) Personnel expenses

	June 30, 06	June 30, 06	June 30, 05	June 30, 05
	<u>H 1 / 06</u>	<u>Q2 / 06</u>	<u>H 1 / 05</u>	<u>Q2 / 05</u>
	T€	T€	T€	T€
Wages and salaries	636	370	637	362
Social contributions	145	75	137	72
Share options granted (in accordance with IFRS 2)	66	33	43	22
	<b>847</b>	<b>478</b>	<b>817</b>	<b>456</b>

On average, the Group had 39 employees over the half-year (June 30, 2006: 40), and MOLOGEN had 25 (June 30, 2005: 27) employees (neither figure includes management or temporary workers).

(21) Depreciation

	June 30, 06	June 30, 06	June 30, 05	June 30, 05
	<u>H 1 / 06</u>	<u>Q2 / 06</u>	<u>H 1 / 05</u>	<u>Q2 / 05</u>
	T€	T€	T€	T€
Intangible assets	100	50	14	7
Property, plant and equipment	102	51	105	52
Current assets (inventories)	15	5	23	23
	<b>217</b>	<b>106</b>	<b>142</b>	<b>82</b>

(22) Other operating expenses

As at June 30, 2006, "Other Operating Expenses" amounted to T€ 910 (June 30, 2005: T€ 1,276).

	June 30, 06	June 30, 06	June 30, 05	June 30, 05
	<u>H 1 / 06</u>	<u>Q2 / 06</u>	<u>H 1 / 05</u>	<u>Q2 / 05</u>
	T€	T€	T€	T€
Marketing/IR	116	72	528	456
Legal and consultancy costs	162	70	291	226
Adjustments to receivables	0	0	3	3
Travel expenses	214	112	112	64
Office space costs	92	47	97	46
Patent costs	71	34	28	14
Administration costs	80	42	64	44
Maintenance	42	26	31	15
Other expenses	133	81	122	76
	<b>910</b>	<b>484</b>	<b>1.276</b>	<b>944</b>

(23) Financial results

The financial results for the reporting period amount to T€ 69 (June 30, 2005: T€ 8) and break down as follows:

	June 30, 06	June 30, 06	June 30, 05	June 30, 05
	<u>H 1 / 06</u>	<u>Q2 / 06</u>	<u>H 1 / 05</u>	<u>Q2 / 05</u>
	T€	T€	T€	T€
Other interest and similar income	73	33	12	5
Other interest and similar expenses	-4	-2	-4	-2
	<b>69</b>	<b>31</b>	<b>8</b>	<b>3</b>

(24) Minority interests

The amount of T€ 0 (June 30, 2005: T€ -1) posted under this item results from the proportion of the period results of Vivotecnia, approx. 10% (June 30, 2005: approx. 3%), allocated to shareholders.

(25) Earnings per share

The weighted average number of shares issued (diluted and undiluted) amounts to 8,357,848 shares as at June 30, 2006 (June 30, 2005: 6,371,226 shares).

The earnings per share (diluted and undiluted) as at June 30, 2006 equal € -0.20 (June 30, 2005: € -0.31)

(26) Financial funds

The liquid funds (6) listed in the consolidated statement of cash flow (Annex 4) as at the balance sheet date breaks down as follows:

	<u>June 30, 2006</u>	<u>June 30, 2005</u>
	T€	T€
Cash and cash at bank	6.049	2.041
Pledged fixed-term deposits	<u>74</u>	<u>74</u>
<b>Liquid funds</b>	<b><u>6.123</u></b>	<b><u>2.115</u></b>

The cash flow from operating activities as at June 30, 2006 contains interest payments in the amount of T€ 4 (June 30, 2005: T€ 4) and interest flows in the amount of T€ 73 (June 30, 2005: T€ 12).

## **D. Other information**

### **Information on the Executive Board**

In the reporting period, the following were members of the MOLOGEN **Executive Board**:

- Prof. Dr. Burghardt Wittig, lecturer, Berlin
- Dr. Matthias Schroff, biochemistry graduate, Berlin
- Mr Dirk Simon, computer science graduate, Berlin

### **Information on the Supervisory Board**

In the reporting period, the following were members of the MOLOGEB **Supervisory Board**:

- Dr. Mathias P. Schlichting, lawyer, Hamburg (Chairman)
- Mr Gregor Kunz, qualified auditor and tax consultant, Berlin
- Prof. Dr. Hans Lutz, lecturer, Zurich, Switzerland

In the reporting period, no reports of related parties holding shares were received by MOLOGEN.

Berlin, August 10, 2006

Mologen AG  
The Executive Board